NASDAQ : RNA
Atrium Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 8.26 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 141.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Atrium Therapeutics, Inc. (RNA) reported revenue of 35.84M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 35.84M | 18.62M | 10.90M | 9.76M |
| Cost of Revenue | 56.04M | 44.27M | 19.20M | 12.65M |
| Gross Profit | -20.20M | -25.65M | -8.30M | -2.89M |
| Selling, General & Admin | 49.01M | 23.98M | 4.92M | 3.50M |
| Operating Expenses | 49.01M | 23.98M | 4.92M | 3.50M |
| Operating Income | -69.21M | -49.63M | -13.22M | -6.39M |
| Other Non Operating Income (Expenses) | 322.00K | -12.00K | 2.00K | 1.00K |
| Pretax Income | -66.13M | -49.64M | -13.22M | -6.38M |
| Income Tax Expense | -142.00K | -142.00K | 11.91M | |
| Net Income | -65.99M | -49.50M | -25.12M | -6.38M |
| Net Income to Common | -65.99M | -49.50M | -25.12M | -6.38M |
| Shares Outstanding (Basic) | 17.11M | 15.51M | ||
| Shares Outstanding (Diluted) | 17.11M | 15.51M | ||
| EPS (Basic) | -3.86 | -3.19 | ||
| EPS (Diluted) | -3.86 | -3.19 | ||
| Free Cash Flow | -56.50M | -42.57M | -22.82M | 56.07M |
| Free Cash Flow Per Share | -3.30 | -2.74 | ||
| Gross Margin | -56.37% | -137.76% | -76.19% | -29.59% |
| Operating Margin | -193.13% | -266.57% | -121.30% | -65.40% |
| Profit Margin | -184.15% | -265.88% | -230.54% | -65.39% |
| Free Cash Flow Margin | -157.66% | -228.67% | -209.41% | 574.25% |
| EBITDA | -68.53M | -49.31M | -13.05M | -6.25M |
| EBITDA Margin | -191.22% | -264.84% | -119.72% | -63.99% |
| D&A For EBITDA | 685.00K | 323.00K | 172.00K | 138.00K |
| EBIT | -69.21M | -49.63M | -13.22M | -6.39M |
| EBIT Margin | -193.13% | -266.57% | -121.30% | -65.40% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Accounts Receivable | 751.00K | |||
| Other Receivables | 100.00K | |||
| Receivables | 100.00K | 751.00K | ||
| Prepaid Expenses | 4.51M | 1.53M | 483.00K | 105.00K |
| Other Current Assets | 6.33M | 1.21M | ||
| Total Current Assets | 275.05M | 2.85M | 483.00K | 856.00K |
| Property, Plant & Equipment | 5.36M | 5.51M | 6.70M | 9.44M |
| Total Assets | 280.51M | 8.35M | 7.19M | 10.29M |
| Accounts Payable | 3.51M | 4.40M | 532.00K | 498.00K |
| Accrued Expenses | 17.27M | 8.69M | 1.44M | 1.50M |
| Current Portion of Leases | 1.68M | 3.67M | 3.84M | 3.64M |
| Current Unearned Revenue | 9.04M | 21.64M | 20.99M | 28.16M |
| Other Current Liabilities | 3.40M | |||
| Total Current Liabilities | 31.51M | 41.80M | 26.80M | 33.80M |
| Long-Term Leases | 2.96M | 6.21M | ||
| Long-Term Unearned Revenue | 33.65M | 28.69M | 37.96M | 40.90M |
| Other Long-Term Liabilities | 775.00K | 574.00K | 574.00K | |
| Total Liabilities | 65.94M | 71.07M | 68.29M | 80.91M |
| Common Stock | 16.00K | -62.71M | -61.11M | -70.62M |
| Shareholders' Equity | 214.58M | -62.71M | -61.11M | -70.62M |
| Total Liabilities & Equity | 280.51M | 8.35M | 7.19M | 10.29M |
| Total Debt | 1.68M | 3.67M | 6.80M | 9.85M |
| Net Cash (Debt) | 262.22M | -3.67M | -6.80M | -9.85M |
| Net Cash Per Share | 15.33 | -0.24 | ||
| Filing Date Shares Outstanding | 17.11M | 15.51M | ||
| Total Common Shares Outstanding | 17.11M | 15.51M | ||
| Working Capital | 243.54M | -38.96M | -26.32M | -32.95M |
| Book Value Per Share | 12.54 | -4.04 | ||
| Tangible Book Value | 214.58M | -62.71M | -61.11M | -70.62M |
| Tangible Book Value Per Share | 12.54 | -4.04 | ||
| Machinery | 5.57M | 2.03M | 1.76M | |
| Leasehold Improvements | 288.00K | 288.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -65.99M | -49.50M | -25.12M | -6.38M |
| Depreciation & Amortization | 685.00K | 323.00K | 172.00K | 138.00K |
| Loss (Gain) From Sale of Assets | 140.00K | 140.00K | ||
| Stock-Based Compensation | 17.88M | 7.68M | 3.18M | 2.51M |
| Other Operating Activities | 1.89M | 430.00K | 12.11M | 195.00K |
| Change in Accounts Receivable | 751.00K | 1.39M | ||
| Change in Accounts Payable | 3.06M | 3.73M | 34.00K | -46.00K |
| Change in Unearned Revenue | -10.84M | -8.62M | -10.11M | 62.78M |
| Change in Other Net Operating Assets | 236.00K | 4.69M | -3.56M | -4.19M |
| Operating Cash Flow | -53.19M | -41.13M | -22.55M | 56.39M |
| Capital Expenditures | -3.31M | -1.45M | -266.00K | -320.00K |
| Investing Cash Flow | -194.86M | -1.45M | -266.00K | -320.00K |
| Other Financing Activities | 320.80M | 42.57M | 22.82M | -56.07M |
| Financing Cash Flow | 320.80M | 42.57M | 22.82M | -56.07M |
| Free Cash Flow | -56.50M | -42.57M | -22.82M | 56.07M |
| Free Cash Flow Margin | -157.66% | -228.67% | -209.41% | 574.25% |
| Free Cash Flow Per Share | -3.30 | -2.74 | ||
| Levered Free Cash Flow | -11.65M | -12.01M | ||
| Unlevered Free Cash Flow | -11.65M | -12.01M | ||
| Change in Working Capital | -7.54M | -200.00K | -12.89M | 59.94M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Debt / Equity Ratio | 0.01 | -0.06 | -0.11 | -0.14 |
| Debt / FCF Ratio | 0.18 | |||
| Net Debt / Equity Ratio | -1.22 | -0.06 | -0.11 | -0.14 |
| Net Debt / EBITDA Ratio | 3.83 | -0.07 | -0.52 | -1.58 |
| Net Debt / FCF Ratio | 4.64 | -0.09 | -0.30 | 0.18 |
| Asset Turnover | 2.40 | 1.25 | ||
| Quick Ratio | 8.38 | 0.00 | 0.02 | |
| Current Ratio | 8.73 | 0.07 | 0.02 | 0.03 |
| Return on Assets (ROA) | -399.25% | -94.53% | ||
| Return on Capital Employed (ROCE) | -27.80% | 148.40% | 67.40% | 27.20% |